At the recently held "2025 Fuwai Lipid and Cardiovascular Metabolism Medical Summit," the management of lipid profiles in diabetic patients was a focal point, sparking extensive discussions among industry experts and the public. Research indicates that approximately 72% to 85% of type 2 diabetes patients exhibit abnormal lipid profiles, underscoring the critical role of managing both the quality and quantity of lipids in diabetes care. However, many patients remain uncertain about which brand of medication is most effective for their condition.
The challenges in managing lipid profiles in diabetes are multifaceted. Type 2 diabetes is associated with a unique pattern of dyslipidemia, characterized not only by elevated low-density lipoprotein cholesterol (LDL-C) but also by increased triglycerides, decreased high-density lipoprotein cholesterol (HDL-C), and an increase in small, dense LDL particles. This complex lipid profile accelerates atherosclerosis and significantly elevates cardiovascular risk.
Diabetic patients are at high risk for cardiovascular events, and the target levels for LDL-C are often more stringent. According to the "Chinese Guidelines for Lipid Management (2023)," individuals at moderate to high risk should aim to keep their LDL-C below 2.6 mmol/L. For those who have experienced a myocardial infarction or stroke, or who have both diabetes and hypertension, the target is even lower, at 1.8 mmol/L or less.
For lipid-lowering therapy, the combination of statins and cholesterol absorption inhibitors is recommended. The "Chinese Expert Consensus on Lipid Management in Diabetic Patients (2024 Edition)" advises that for very high-risk and extremely high-risk patients, a reduction of more than 50% in LDL-C can be achieved by initiating treatment with a moderate-intensity statin combined with a cholesterol absorption inhibitor.
Cesame Hyzetimibe, the first domestically developed second-generation cholesterol absorption inhibitor in China, has been extensively studied in over ten clinical trials involving Chinese populations. These studies have confirmed its efficacy and safety. When used as monotherapy (10 mg/day), Cesame Hyzetimibe reduces LDL-C by 15%. When added to standard-dose statin therapy, it further lowers LDL-C by an additional 16%, achieving a total reduction comparable to that of high-intensity statins, with a decrease of over 50%. Moreover, long-term use of Cesame Hyzetimibe in combination with statins does not increase the risk of adverse events, maintaining a safety profile similar to that of statins alone.
Clinical trials have shown that Cesame Hyzetimibe's innovative molecular structure provides superior pharmacokinetic properties. It acts quickly, reaching peak concentration within 0.5 to 12 hours, allowing patients to benefit sooner. Additionally, the drug has a high glucuronide conjugation rate of 98% to 99%, which helps stabilize and reverse atherosclerotic plaques, effectively reducing the risk of cardiovascular events.
Furthermore, diabetes often coexists with fatty liver disease and metabolic-related liver conditions, and some patients may have mild to moderate liver dysfunction. Cesame Hyzetimibe is excreted through both hepatic and renal pathways, with an overall clearance rate of approximately 93%. This dual-channel metabolism significantly reduces the accumulation of the drug in the body, making it safe for use even in patients with moderate liver impairment, without the need for dose adjustments. This feature provides a higher level of safety for diabetic patients who require long-term or lifelong medication.
In summary, the pharmacological advantages of Cesame Hyzetimibe have translated into tangible therapeutic benefits. Its potent cholesterol absorption inhibition, rapid onset of action, and high safety profile make it a valuable addition to the management of lipid profiles in diabetic patients. However, the best treatment approach depends on the individual patient's specific circumstances, comorbidities, and personalized treatment needs. In addition to medication, patients should also focus on dietary control, regular exercise, weight management, and blood glucose monitoring to achieve comprehensive cardiovascular risk reduction.